The Association Between Antidepressant Effect of SSRIs and Astrocytes: Conceptual Overview and Meta‐analysis of the LiteratureCitation formats

  • External authors:
  • Beina Chen
  • Manman Zhang
  • Ming Ji
  • Wenliang Gong
  • Binjie Chen
  • Robert Zorec
  • Matjaž Stenovec
  • Baoman Li

Standard

The Association Between Antidepressant Effect of SSRIs and Astrocytes: Conceptual Overview and Meta‐analysis of the Literature. / Chen, Beina; Zhang, Manman; Ji, Ming; Gong, Wenliang; Chen, Binjie; Zorec, Robert; Stenovec, Matjaž; Verkhratsky, Alexei; Li, Baoman.

In: Neurochemical research, 01.02.2021.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Chen, Beina ; Zhang, Manman ; Ji, Ming ; Gong, Wenliang ; Chen, Binjie ; Zorec, Robert ; Stenovec, Matjaž ; Verkhratsky, Alexei ; Li, Baoman. / The Association Between Antidepressant Effect of SSRIs and Astrocytes: Conceptual Overview and Meta‐analysis of the Literature. In: Neurochemical research. 2021.

Bibtex

@article{8763a767c4104497b3012eae28127e1a,
title = "The Association Between Antidepressant Effect of SSRIs and Astrocytes: Conceptual Overview and Meta‐analysis of the Literature",
abstract = "Major depressive disorders (MDD) a worldwide psychiatric disease, is yet to be adequately controlled by therapies; while the mechanisms of action of antidepressants are yet to be fully characterised. In the last two decades, an increasing number of studies have demonstrated the role of astrocytes in the pathophysiology and therapy of MDD. Selective serotonin reuptake inhibitors (SSRIs) are the most widely used antidepressants. It is generally acknowledged that SSRIs increase serotonin levels in the central nervous system by inhibiting serotonin transporters, although the SSRIs action is not ideal. The SSRIs antidepressant effect develops with considerable delay; their efficacy is low and frequent relapses are common. Neither cellular nor molecular pharmacological mechanisms of SSRIs are fully characterised; in particular their action on astrocytes remain underappreciated. In this paper we overview potential therapeutic mechanisms of SSRIs associated with astroglia and report the results of meta-analysis of studies dedicated to MDD, SSRIs and astrocytes. In particular, we argue that fluoxetine, the representative SSRI, improves depressive-like behaviours in animals treated with chronic mild stress and reverses depression-associated decrease in astrocytic glial fibrillary acidic protein (GFAP) expression. In addition, fluoxetine upregulates astrocytic mRNA expression of 5-hydroxytriptamin/serotonin2B receptors (5-HT2BR). In summary, we infer that SSRIs exert their anti-depressant effect by regulating several molecular and signalling pathways in astrocytes.",
author = "Beina Chen and Manman Zhang and Ming Ji and Wenliang Gong and Binjie Chen and Robert Zorec and Matja{\v z} Stenovec and Alexei Verkhratsky and Baoman Li",
year = "2021",
month = feb,
day = "1",
doi = "10.1007/s11064-020-03225-6",
language = "English",
journal = "Neurochemical research",
issn = "0364-3190",
publisher = "Springer Nature",

}

RIS

TY - JOUR

T1 - The Association Between Antidepressant Effect of SSRIs and Astrocytes: Conceptual Overview and Meta‐analysis of the Literature

AU - Chen, Beina

AU - Zhang, Manman

AU - Ji, Ming

AU - Gong, Wenliang

AU - Chen, Binjie

AU - Zorec, Robert

AU - Stenovec, Matjaž

AU - Verkhratsky, Alexei

AU - Li, Baoman

PY - 2021/2/1

Y1 - 2021/2/1

N2 - Major depressive disorders (MDD) a worldwide psychiatric disease, is yet to be adequately controlled by therapies; while the mechanisms of action of antidepressants are yet to be fully characterised. In the last two decades, an increasing number of studies have demonstrated the role of astrocytes in the pathophysiology and therapy of MDD. Selective serotonin reuptake inhibitors (SSRIs) are the most widely used antidepressants. It is generally acknowledged that SSRIs increase serotonin levels in the central nervous system by inhibiting serotonin transporters, although the SSRIs action is not ideal. The SSRIs antidepressant effect develops with considerable delay; their efficacy is low and frequent relapses are common. Neither cellular nor molecular pharmacological mechanisms of SSRIs are fully characterised; in particular their action on astrocytes remain underappreciated. In this paper we overview potential therapeutic mechanisms of SSRIs associated with astroglia and report the results of meta-analysis of studies dedicated to MDD, SSRIs and astrocytes. In particular, we argue that fluoxetine, the representative SSRI, improves depressive-like behaviours in animals treated with chronic mild stress and reverses depression-associated decrease in astrocytic glial fibrillary acidic protein (GFAP) expression. In addition, fluoxetine upregulates astrocytic mRNA expression of 5-hydroxytriptamin/serotonin2B receptors (5-HT2BR). In summary, we infer that SSRIs exert their anti-depressant effect by regulating several molecular and signalling pathways in astrocytes.

AB - Major depressive disorders (MDD) a worldwide psychiatric disease, is yet to be adequately controlled by therapies; while the mechanisms of action of antidepressants are yet to be fully characterised. In the last two decades, an increasing number of studies have demonstrated the role of astrocytes in the pathophysiology and therapy of MDD. Selective serotonin reuptake inhibitors (SSRIs) are the most widely used antidepressants. It is generally acknowledged that SSRIs increase serotonin levels in the central nervous system by inhibiting serotonin transporters, although the SSRIs action is not ideal. The SSRIs antidepressant effect develops with considerable delay; their efficacy is low and frequent relapses are common. Neither cellular nor molecular pharmacological mechanisms of SSRIs are fully characterised; in particular their action on astrocytes remain underappreciated. In this paper we overview potential therapeutic mechanisms of SSRIs associated with astroglia and report the results of meta-analysis of studies dedicated to MDD, SSRIs and astrocytes. In particular, we argue that fluoxetine, the representative SSRI, improves depressive-like behaviours in animals treated with chronic mild stress and reverses depression-associated decrease in astrocytic glial fibrillary acidic protein (GFAP) expression. In addition, fluoxetine upregulates astrocytic mRNA expression of 5-hydroxytriptamin/serotonin2B receptors (5-HT2BR). In summary, we infer that SSRIs exert their anti-depressant effect by regulating several molecular and signalling pathways in astrocytes.

U2 - 10.1007/s11064-020-03225-6

DO - 10.1007/s11064-020-03225-6

M3 - Article

JO - Neurochemical research

JF - Neurochemical research

SN - 0364-3190

ER -